The program of physical rehabilitation for patients with coronary heart disease and hypertensive disease

2016 ◽  
Vol 94 (1) ◽  
pp. 36-38
Author(s):  
Irina N. Makarova ◽  
S. M. Starikov ◽  
D. D. Bolotov
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Functional State ◽  
High Efficiency ◽  
Physical Load ◽  
Hemodynamic Parameters ◽  
Special Program ◽  
Hypertensive Disease ◽  
Before And After

The authors demonstrate the importance of individual criteria for the choice of dosed physical load for the patients with cardiological problems during hospitalization. The analysis of the functional state and hemodynamic parameters included 68 patients with various cardiovascular diseases before and after performance of the special program ofphysical rehabilitation. The results suggest high efficiency of the proposed treatment and good prospects for further studies in this field.

scholarly journals Modelling the impact of compliance with WHO salt recommendations on cardiovascular mortality in Russia

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
D Mukaneeva ◽  
A Kontsevaya ◽  
YU Balanova ◽  
M Khudyakov ◽  
O Drapkina
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Salt Intake ◽  
High Salt ◽  
Baseline Scenario ◽  
Hypertensive Disease ◽  
Salt Consumption ◽  
High Salt Intake ◽  
The Impact

Abstract Funding Acknowledgements Type of funding sources: None. Introduction High salt intake is considered the primary diet-related risk factor (being responsible for 3 million deaths and 70 million DALYs), because of its association with NCDs, such as cardiovascular diseases (ischemic heart disease, stroke, and hypertension). The World Health Organization (WHO) recommended daily salt intake is known to be <5 g / day (2 g sodium per day). Despite strong evidence indicating that high salt intake relates to chronic diseases and mortality, most adults do not comply with dietary recommendations. The average amount of salt consumed per day is significantly higher and amounts to 11.35 g/day among Russian adults (2018). The purpose of this study is to model the impact of following the national salt consumption recommendations in decreasing N of death  attributable to excessive salt consumption. Methods This study provides a health impact evaluation, which models the effect of sodium reduction on mortality associated with blood pressure and CVD in 2018 in Russia. Cardiovascular disease included coronary heart disease, stroke, hypertensive disease, heart failure, aortic aneurysm, pulmonary embolism and rheumatic heart disease. The observed salt intake from the Russian National Health Survey of 2018 was used to determine the reference (baseline) scenario and the counterfactual scenario considered that average salt consumption was reduced to 5g/day. A comparative risk assessment model, the Preventable Risk Integrated ModEl (PRIME) was used to estimate the deaths from cardiovascular diseases that could be averted or postponed based on the sodium recommendation scenario compared to the baseline scenario. The sensitivity of the model to the results from the meta-analyses was assessed with Monte Carlo simulations. Results In 2018, an estimated 104 602 (95%: 46 832, 154 233) deaths from CVDs could have been prevented if the average salt consumption had been reduced to 5 g/day in Russia. Coronary heart disease (CHD), stroke and hypertensive disease accounted for 97% of these deaths. The modelled reduction in deaths for coronary heart disease was 59 454, for stroke 37 306 and for hypertensive disease 4 833. Conclusion A considerable number of lives could be saved if Russians adhered to the national salt intake recommendations.

Prediction of atherosclerosis in children and the possibility of early prevention of coronary heart disease

1999 ◽  
Vol 80 (4) ◽  
pp. 296-297
Author(s):  
O. I. Pikuza ◽  
V. N. Oslopov ◽  
H. M. Vakhitov ◽  
A. A. Babushkina ◽  
S. E. Nikolsky
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Artery ◽  
Cardiovascular Diseases ◽  
Childhood And Adolescence ◽  
Early Prevention ◽  
Cerebrovascular Pathology ◽  
Artery Disease

Cardiovascular diseases caused by atherosclerosis (coronary artery disease, cerebrovascular pathology, etc.) are responsible for 40-50% of all deaths in adults. Of particular concern to clinicians is the emerging unfavorable tendency to "rejuvenate" these diseases. Currently, the fact that atherosclerosis (AS) begins to form in childhood and adolescence is indisputable.

Genetic Polymorphisms, LDL-C and sdLDL-C Help Optimize Coronary Heart Disease (CHD) Therapy

2021 ◽  
Author(s):  
Ruozhu Dai ◽  
Huilin Zhuo ◽  
Wei Wang ◽  
Xinjun Wang ◽  
Xiaoyu Zhao
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Genetic Polymorphisms ◽  
Therapy Monitoring ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Healthy People ◽  
Risk Indicator ◽  
Before And After ◽  
A Prospective Study

Abstract Background: Low-density lipoprotein cholesterol (LDL-C) and small, dense LDL-C (sdLDL-C) are important risk indicator of coronary heart disease (CHD), but their application in therapy monitoring of CHD is still far from being elucidated. Following the concept of precision medicine, we investigated whether the scientific medication based on medication-sensitive genes can reverse the LDL-C and sdLDL-C status in human bloodstream, so as to reveal the possibility of them as a monitoring indicator of CHD efficacy.Methods: A prospective study of CHD cohort containing 208 Chinese CHD patients (158 males and 50 females) and 20 healthy people (14 males and 6 females) was recruited. LDL-C and its subfractions were detected before and after treatment. Polymorphism of medication-sensitive genes, including SLCO1B1 (rs4149056, 521T>C), CYP2C19*2 (rs4244285, c.681G>A), and CYP2C19*3 (rs4986893, c.636G>A) were detected for medication guidance.Results: Nearly half of Chinese CHD patients (47.60%, 99/208) had genetic polymorphisms with homozygous or heterozygous mutations within these three genes. LDL-1 and LDL-2, subfractions of LDL-C, had a 100% positive rate in CHD patients and healthy people. However, sdLDL-C components of LDL-5 to LDL-7 were only enrichment in CHD patients. Moreover, the mean amount of sdLDL-C subfractions in CHD patients was significantly higher than that in healthy people. Among 180 patients with treatment remission, 81.67% (n=147) of CHD patients had decreased LDL-C, while 61.67% (n=111) of patients had decreased sdLDL-C.Conclusion: sdLDL-C has better accuracy on CHD screening than LDL-C, while LDL-C was more suitable for CHD therapy monitoring. Combined medication-sensitive genes polymorphism, LDL-C and sdLDL-C detection would optimize the treatment strategy for CHD patients.

Abstract 13769: Assessing the Risk for Cardiovascular Diseases According to Lipoprotein(a) Levels

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Narek A Tmoyan ◽  
Marat V Ezhov ◽  
Olga I Afanasieva ◽  
Uliana V Chubykina ◽  
Elena A Klesareva ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Carotid Artery ◽  
Lower Extremity ◽  
Carotid Artery Disease ◽  
Lipoprotein A ◽  
Artery Disease ◽  
Lower Extremity Artery Disease

Introduction: There is no common opinion about threshold lipoprotein(a) [Lp(a)] concentration for atherosclerotic cardiovascular diseases (ASCVD) risk. Different clinical guidelines and consensus documents postulated cut-off Lp(a) level as 30 mg/dL or 50 mg/dL. We assessed the concentration of Lp(a) that associated with ASCVD of different locations. Methods: The study included 1224 patients with ASCVD. Lp(a) concentration was measured by enzyme-linked immunosorbent assay in serum. Patients were divided into 3 groups: group I - Lp(a)<30 mg/dL, group II - 30≤Lp(a)<50 mg/dL, group III - Lp(a)≥50 mg/dL (table). Results: Coronary heart disease, carotid artery disease, lower extremity artery disease, myocardial infarction and ischemic stroke were diagnosed in 61%; 34%; 23%; 42% and 11% patients, respectively. Lower extremity artery disease, carotid artery disease and myocardial infarction were more frequent in patients with Lp(a) concentration from 30 to 50 mg/dL compared to patients with Lp(a) <30 mg/dL: 36%, 41%, 48% vs. 17%, 30%, 36% respectively, p<0.01 for all. Subjects with Lp(a) 30-50 mg/dL (n=182, 15%) had a greater odds ratio of lower extremity artery disease, carotid artery disease and myocardial infarction compared to patients with Lp(a) <30 mg/dL (table). ROC analysis demonstrated that Lp(a) cut-off levels for lower extremity artery disease, carotid artery disease, coronary heart disease and myocardial infarction were 26; 21; 37 and 36 mg/dL, respectively. Conclusions: Our results demonstrate that in case of Lp(a) cut-off level of 50 mg/dL about 15% of patients are underestimated for the risk of ASCVD. Lp(a) cut-off level for ASCVD is between 20 and 40 mg/dL regarding the atherosclerosis location.

Cardiovascular diseases

2019 ◽  
pp. 587-615
Author(s):  
Joseph De Bono ◽  
Anli Yue Zhou
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Congenital Heart ◽  
Special Section ◽  
Hazardous Substances ◽  
Evidence Based ◽  
Cardiac Devices ◽  
Implantable Cardiac Devices ◽  
The Uk

Cardiovascular diseases are one of the leading causes of morbidity and mortality in the UK. Cardiovascular diseases can affect those in employment and can limit working capacity. Multiple considerations should be taken into account when assessing return to work, including psychosocial factors. This chapter provides a comprehensive and up-to-date evidence-based overview of common cardiovascular diseases such as coronary heart disease, valvular disease, congenital heart disease, hypertension, syncope, and implantable cardiac devices including pacemakers (with a special section on implantable devices and electromagnetic fields). Topics of interest also covered within this chapter include travel, firefighters, stress, shift working, hazardous substances, hot conditions, and driving.

Effectiveness of Long-term Heparin-induced Extracorporeal LDL Precipitation (HELP) in Improving Coronary Calcifications

2003 ◽  
Vol 26 (3) ◽  
pp. 252-255 ◽  
Author(s):  
A. Ramunni ◽  
L.F. Morrone ◽  
G. Baldassarre ◽  
E. Montagna ◽  
A. Saracino ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Evidence ◽  
Ldl Cholesterol ◽  
Clinical Manifestations ◽  
Mean Value ◽  
Mean Values ◽  
Plasma Pool ◽  
Before And After

There is clear clinical evidence that a drastic lowering of plasma LDL- Cholesterol (LDL) concentrations significantly reduces the rate of total and coronary mortality as well as the incidence of cardiovascular events in high risk hypercholesterolemic patients. We describe the case of a 51-year-old woman with coronary heart disease (CHD) who presented with increasing angina on exertion in 1995, at the age of 45. She suffered from a heterozygous familial hypercholesterolemia and in 1985 her total cholesterol (TCHO) was 328±62 mg/dl (mean value of ten analysis). After ten years of statins her mean values (20 analysis, 2 per year) were: TCHO 259±71, LDL 209±47, HDL 35±7 mg/dl. Coronary angiography (CA) performed in 1995 disclosed three vessel coronary heart disease with significant stenoses of the distal right coronary artery, multiple calcifications of the interventricularis artery and multiple plaques with significant stenoses in the ramus circumflexus. The woman underwent coronary by-pass surgery. Thereafter the patient was treated for six years with HELP in biweekly intervals, in combination with statins. TCHO, LDL, HDL and fibrinogen (fb) levels were measured before and after each treatment. Their mean values for an amount of 120 sessions were: TCHO pre 216±23, post 111±18 LDL pre 152±16 post 67±18, HDL pre 42±5 post 35±4 fb pre 306±48 post 125±31. In 2001 a new CA was performed. Calcifications disappeared and stenoses were identical to the previous CA or reduced. There were no further clinical manifestations of CHD. We trust that the clinical benefit of the HELP procedure will be substantial for those patients who have problems in clearing LDL from their plasma pool and who are at the same time sensitive to elevated LDL levels by the development of premature coronary sclerosis.

Sign in / Sign up

Export Citation Format

Share Document